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Abstract
Background: Noninvasive prenatal diagnosis of fetal aneuploidy by maternal plasma analysis is challenging owing to the
low fractional and absolute concentrations of fetal DNA in maternal plasma. Previously, we demonstrated for the first time
that fetal DNA in maternal plasma could be specifically targeted by epigenetic (DNA methylation) signatures in the placenta.
By comparing one such methylated fetal epigenetic marker located on chromosome 21 with another fetal genetic marker
located on a reference chromosome in maternal plasma, we could infer the relative dosage of fetal chromosome 21 and
noninvasively detect fetal trisomy 21. Here we apply this epigenetic-genetic (EGG) chromosome dosage approach to detect
Edwards syndrome (trisomy 18) in the fetus noninvasively.
Principal Findings: We have systematically identified methylated fetal epigenetic markers on chromosome 18 by
methylated DNA immunoprecipitation (MeDIP) and tiling array analysis with confirmation using quantitative DNA
methylation assays. Methylated DNA sequences from an intergenic region between the VAPA and APCDD1 genes (the VAPA-
APCDD1 DNA) were detected in pre-delivery, but not post-delivery, maternal plasma samples. The concentrations correlated
positively with those of an established fetal genetic marker, ZFY, in pre-delivery maternal plasma. The ratios of methylated
VAPA-APCDD1(chr18) to ZFY(chrY) were higher in maternal plasma samples of 9 male trisomy 18 fetuses than those of 27
male euploid fetuses (Mann-Whitney test, P=0.029). We defined the cutoff value for detecting trisomy 18 fetuses as
mean+1.96 SD of the EGG ratios of the euploid cases. Eight of 9 trisomy 18 and 1 of 27 euploid cases showed EGG ratios
higher than the cutoff value, giving a sensitivity of 88.9% and a specificity of 96.3%.
Conclusions: Our data have shown that the methylated VAPA-APCDD1 DNA in maternal plasma is predominantly derived
from the fetus. We have demonstrated that this novel fetal epigenetic marker in maternal plasma is useful for the
noninvasive detection of fetal trisomy 18.
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Introduction
Fetal chromosomal aneuploidies are the main reasons for
pregnant women to seek prenatal diagnosis [1]. Definitive
diagnosis of fetal aneuploidy often requires obtaining fetal genetic
materials by invasive procedures, which carry a risk of procedure-
associated fetal loss [2]. The presence of fetal DNA in maternal
plasma has opened up new opportunities for noninvasive prenatal
diagnosis [3]. However, the noninvasive detection of fetal
aneuploidy in maternal plasma is complicated by the low
fractional concentration (3–10%) of fetal DNA, which co-exists
with a large background of maternal DNA [4,5].
To detect fetal Down syndrome noninvasively, we and other
researchers have applied massively parallel genomic sequencing to
determine the proportional amounts of chromosome 21 DNA
molecules in maternal plasma [6–8]. This approach entails the
analysis of millions of DNA molecules, derived from both the
mother and the fetus, in maternal plasma. As an alternative to the
PLoS ONE | www.plosone.org 1 November 2010 | Volume 5 | Issue 11 | e15069still technically and bioinformatically complex massively parallel
sequencing-based approach, we have developed other approaches
by targeting fetal-specific DNA or RNA molecules in maternal
plasma [9–12].
Previous findings suggest that the placenta is the major source of
cell-free fetal nucleic acids in maternal plasma [13–15], whereas
maternal blood cells are the major source of maternal nucleic acids
in maternal plasma [16]. Thus, we have used epigenetic signatures
specific to the placenta but not maternal blood cells to target fetal
DNA in maternal plasma [14,17–19]. We have developed a
placental epigenetic signature, namely the unmethylated promoter
of the serpin peptidase inhibitor, clade B (ovalbumin), member 5
(SERPINB5, NM_002639) gene, into a fetal epigenetic (DNA
methylation) marker. Since this fetal epigenetic marker is located
on chromosome 18, it is feasible to detect fetal trisomy 18 by
assessing the ratio of the alleles in fetuses who are heterozygous for
this marker [20]. However, this approach is only applicable to
fetuses polymorphic for the marker. Thus, we developed an
alternative approach, the epigenetic-genetic (EGG) chromosome
dosage approach, with potentially wider population coverage.
We have recently applied the EGG approach for the
noninvasive detection of fetal trisomy 21 [11]. This EGG analysis
involves a fetal epigenetic marker, holocarboxylase synthetase (HLCS,
NM_002639) gene, which is found to be hypermethylated in the
placenta in comparison to maternal blood cells. Comparing this
fetal epigenetic marker, which is located on the chromosome 21,
with a fetal genetic marker on a reference chromosome unaffected
by trisomy 21, we could infer the relative dosage of fetal
chromosome 21 by analyzing maternal plasma DNA [11]. Since
any paternally-inherited fetal sequences that are not found in the
pregnant woman (e.g. Y-chromosomal sequences for male fetuses
or polymorphic sequences inherited only from the father for both
male and female fetuses) and are located on a reference
chromosome can serve as the fetal genetic marker for the EGG
analysis, potentially all fetuses in the general population may be
covered.
Yet, if we use the EGG approach to detect the small increase
(,1.5-fold) in the dosage of fetal chromosome 21 relative to any
other unaffected fetal chromosome in maternal plasma samples
collected from pregnancies involving a Down syndrome fetus, an
analytical platform of high precision is required. The bisulfite-
based detection method of fetal epigenetic markers can only offer
limited precision, because bisulfite has been reported to degrade
.90% of the input DNA [21]. A bisulfite-independent method
using methylation-sensitive restriction enzyme that digests only
unmethylated, but not methylated DNA has been developed to
detect methylated fetal epigenetic marker [17]. Adopting this
method to detect the methylated HLCS DNA molecules in
maternal plasma, we have achieved an analytical precision that
was high enough to distinguish between trisomy 21 and euploid
fetuses noninvasively [11].
Therefore, the fetal epigenetic marker suitable for the EGG
approach has to be resistant to digestion by methylation-sensitive
restriction enzymes in maternal plasma. In other words, we need a
fetal epigenetic marker that is hypermethylated in the placenta, the
predominant source of fetal DNA in maternal plasma [14], and is
located on the potentially aneuploid chromosome. Most of the
earlier studies searched for fetal epigenetic markers only within
selected genomic loci on chromosome 21 [11,22,23]. Using
methylated DNA immunoprecipitation (MeDIP) and tiling array
analysis [24], other investigators have expanded the search to
chromosome 18 and reported numerous loci as potential fetal
epigenetic markers [25]. However, no studies have validated
whether these MeDIP-identified markers are detectable in
maternal plasma, let alone their fetal-specificity in maternal
plasma and clinical application.
In this study, we aimed to identify fetal methylated markers on
chromosome 18 by MeDIP in a systematic way, and to confirm its
detectability and fetal-specificity in maternal plasma. Furthermore,
we applied this marker to develop an EGG test for the noninvasive
detection of fetal trisomy 18.
Materials and Methods
Objectives
To systematically test if there are any genomic loci on
chromosome 18 that are hypermethylated in the placenta,
compared with maternal blood cells, we profiled the DNA
methylation levels in the two tissue types by MeDIP and tiling
array (MeDIP-chip). To test if the methylated DNA of such a locus
is fetal specific in maternal plasma, we measured its plasma
concentration before and after delivery of the fetus. To test if this
methylated fetal epigenetic marker in maternal plasma can be used
to detect fetuses with trisomy 18 using the EGG approach, we
measured its concentrations relative to a fetal genetic marker by
digital PCR.
Ethics approval
This study was conducted according to the principles expressed
in the Declaration of Helsinki. Ethics approval from the Joint
Chinese University of Hong Kong-New Territories East Cluster
Clinical Research Ethics Committee and the respective institu-
tional review broads was obtained. All patients provided written
informed consent for the collection of samples and subsequent
analysis.
Subjects and sample collection
Women with singleton pregnancies attending the respective
hospitals in Hong Kong and the UK were recruited (File S1).
Placental tissues were collected from first- and third-trimester
pregnant women undergoing pregnancy termination and elective
cesarean section, respectively. Maternal peripheral blood samples
were collected just before and 24 hours after the obstetrics
procedures. Additionally, blood samples were collected from first-
and second-trimester pregnant women attending antenatal care.
The trisomy 18 status of the fetus was confirmed by full
karyotyping of chorionic villus samples. Blood samples were also
collected from non-pregnant individuals as negative controls for
validating the fetal-specificity of the candidate marker in plasma.
Sample processing
Maternal plasma was harvested from EDTA-blood by our
previously established double-centrifugation protocol [26]. The
maternal blood cell sample portion was recentrifuged at 2,5006g
for removal of any residual plasma. Placenta was rinsed
thoroughly in phosphate buffered saline to remove blood. DNA
was extracted from plasma, blood cells and the placenta with the
methods described in File S1.
MeDIP and tiling array (MeDIP-chip) analysis
The DNA sample was sonicated and subjected to MeDIP by
antibody specific for methylated cytosine [24]. The immunopre-
cipitated product was amplified, labeled and hybridized on the
GeneChip Human Tiling 2.0R Arrays (Affymetrix). Genomic loci
with significantly higher DNA methylation in the placenta, relative
to maternal blood cells, were identified by the Tiling Array
Software (TAS) version 1.1 and the Model-based Analysis of
Noninvasive Prenatal Detection of Edwards Syndrome
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S1 [27,28].
Rapid and quantitative DNA methylation analysis by the
Epityper
MeDIP-identified locus was analyzed by a quantitative DNA
methylation assay, the Epityper (Sequenom) [29](File S1). Briefly,
the genomic locus of interest in a bisulfite-converted DNA sample
was subjected to PCR amplification by primers listed in Table S1,
in vitro transcription into RNA, and uracil-specific cleavage on the
complementary strand. The product derived from PCR amplicons
would therefore be fragmented. Fragments derived from the
methylated and unmethylated DNA molecules would have
different masses due to the difference in nucleotide sequence at
the CpG site caused by bisulfite conversion. The mass differences
were readily resolved and quantified as distinct peaks by matrix-
assisted laser desorption and ionization time-of-flight (MALDI-
TOF) mass spectrometry. In the Epityper, the DNA methylation
level of one or more CpG sites in any one cleaved fragment was
reported as an integral unit, namely a CpG unit. For each CpG
unit, a methylation index (MI) was calculated as the ratio of the
methylated peak height to the sum of the methylated and
unmethylated peak heights.
Priority for Epityper analysis was given for MeDIP-identified
loci that would (i) allow appropriate PCR design, including a high
annealing temperature of the primers; (ii) result in Epityper assays
with the maximum number of detectable fragments (CpG units),
the masses of which were within the detection range of the mass
spectrometer; and (iii) allow specific PCR amplification from
bisulfite-converted DNA. (i)-(ii) were mainly calculated by the
Epidesigner 2.0 program (Sequenom); and (iii) was checked by the
BiSearch search tool [30]. Occurrence of genomic variations in
the analyzed regions were checked using the Database of Genomic
Variants (http://projects.tcag.ca/variation/) [31]. We made sure
that there was no reported variant of higher than 1% frequency in
the regions we analyzed.
Single-base single-molecule DNA methylation analysis by
bisulfite genomic sequencing
To quantify DNA methylation at the resolution of single CpG
site in a single molecule, bisulfite genomic sequencing was
performed [32]. Briefly, a genomic locus in the bisulfite-converted
DNA was amplified by PCR primers (Table S1). The PCR
products were cloned and segregated as colonies, each represent-
ing a single molecule for sequencing (File S1). For each CpG site in
a DNA sample, a MI was calculated as the ratio of the number of
methylated clones to the total number of clones sequenced.
Conventional quantitative PCR assays for VAPA-APCDD1,
ZFY and b-actin DNA
DNA samples, which had been subjected to digestion by
methylation-sensitive restriction enzyme (File S1) or mock
digestion by 50% glycerol instead of an enzyme, were then
analyzed by 3 quantitative polymerase chain reaction (qPCR)
assays. One qPCR assay was designed to target an intergenic
region between the VAMP (vesicle-associated membrane protein)-
associated protein A, 33 kDa (VAPA, NM_003574) gene and the
adenomatosis polyposis coli down-regulated 1 (APCDD1, NM_153000)
gene. Another assay, targeting the zinc finger protein, Y-linked (ZFY,
NM_003411), an established genetic marker for detecting fetal
DNA in maternal plasma of pregnancies bearing male fetuses, was
adopted from our previous study [5]. The third assay was designed
to target a completely unmethylated region (positive control for
methylation-sensitive restriction enzyme digestion) of the b-actin
(ACTB, NM_001101) gene.
All 3 assays involved hydrolysis probes for detection. The
primer and probe sequences and reaction conditions are listed in
Tables S2 and S3. Concentrations of each target were quantified
by a standard calibration curve constructed with known
concentrations of a male genomic DNA sample. Any signals
detected below the limit of detection (3 copies/PCR for all 3
qPCR assays), as determined by the method in File S1, were
considered undetectable. Eight no template controls (water only)
were included in every PCR run.
Digital PCR assays for EGG dosage analysis
Since high analytical precision is required for chromosome
dosage analysis, this part of the study was performed by digital
PCR [33]. We performed digital PCR through the dilution of the
DNA sample to an average concentration of one template
molecule in every two reaction wells [34]. This diluted DNA
sample was then distributed to hundreds of reaction wells on a
384-well plate for PCR amplification of VAPA-APCDD1, ZFY and
b-actin DNA. Primer and probe sequences and reaction conditions
are listed in Tables S2 and S3. The actual number of template
molecules was calculated by the direct counting of the number of
positive wells followed by correction for the Poisson distribution
(File S1).
Statistical analysis
Statistical analyses were performed with the Sigma Stat v3.5
(Systat).
Results
Systematic identification of chromosome 18 loci
hypermethylated in the placenta by MeDIP and the
Epityper
We have embarked on studying DNA methylation levels of the
entire chromosome 18, which contains about 351,500 CpG sites in
74.7 million bases of non-repetitive DNA sequence [35]. Ten
DNA samples from 5 first-trimester euploid placentas and 5 first-
trimester maternal blood cell samples were subjected to MeDIP
and tiling array analysis. The array interrogated DNA methylation
level every 35 bases (average inter-probe distance) on essentially all
the non-repetitive DNA sequences of the entire chromosome.
Genomic loci with a signal log ratio between the placenta and
maternal blood cells of .0.4 in the TAS analysis or with a
P,10
25 in the MAT analysis were considered as hypermethylated
in the placenta. We identified 3,043 CpG sites located in 178 loci
(68 and 110 loci from the TAS and MAT algorithms, respectively)
with higher DNA methylation levels in the placenta, relative to
maternal blood cells. We found that 140 loci (79%) were located
within genes and the remaining 38 loci (21%) were located in the
intergenic regions. The results from the TAS and MAT algorithms
are listed in Table S4 and Table S5, respectively. The data
discussed in this publication have been deposited in NCBI’s Gene
Expression Omnibus [36], and are accessible through GEO Series
accession number GSE22837.
Selecting for CpG sites with high DNA methylation levels
in the placenta. Quantitative DNA methylation levels at the
resolution of CpG sites are required for developing fetal epigenetic
markers in maternal plasma. For this purpose, we analyzed the
MeDIP-identified loci by quantitative DNA methylation assays,
the Epityper, which were less labor-intensive and time-consuming
than bisulfite sequencing, because it did not involve cloning and
sequencing [29,37]. Priority was given for 370 CpG units (located
Noninvasive Prenatal Detection of Edwards Syndrome
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platform (Figure 1A). For each CpG unit, we compared the DNA
methylation levels of two first-trimester placentas, with two first-
trimester maternal blood cell samples (Figure 1B and Table S6).
To select CpG units potentially useful for developing fetal
epigenetic markers in maternal plasma, we identified CpG units
with a methylation index (MI) #0.20 in the maternal blood cells
(criterion #1), and with a difference in MI of $0.50 between the
placenta and maternal blood cells (criterion #2). These criteria
were adopted with slight modification from our previous study in
developing fetal markers in maternal plasma [22]. Among the 370
CpG units analyzed by the Epityper, 40 CpG units, located in 8
MeDIP-identified loci, fulfilled both criteria #1 and #2 (Table 1;
Figure 1B, highlighted as green bars). Three or more potentially
useful CpG units were found in each of 5 MeDIP-identified loci
(Table 1, top 5 loci). Thus, we further confirmed these
observations in more cases. The majority of the analyzed CpG
units in these 5 loci were confirmed to possess significantly higher
DNA methylation levels in 5 first-trimester placentas, relative to 5
first-trimester maternal blood cell samples (Figure 2; Table S7,
Mann-Whitney test, p,0.05).
Selecting for CpG sites with low inter-individual variation
in placental DNA methylation levels. We then assessed the
inter-individual variations of the MI of the 5 selected loci in 10
Figure 1. Quantitative DNA methylation levels by the Epityper. (A) Genomic locations of the loci (vertical bars) that were analyzed by the
Epityper. (B) Two tracks, each with 5 panels, are shown. First panel (from top). Bar graph of methylation indices (MI) in maternal blood cells (Y-axis)
against the chromosomal locations of the CpG units (X-axis, a categorical axis) within the indicated locus (a-z, fifth panel). Each bar represents one
CpG unit. The chromosomal locations and MI of each CpG unit are listed in Table S6. A CpG unit is potentially useful for marker development if it
fulfills criterion #1: MI in maternal blood cells #0.2 (lower than the dotted line, highlighted as green bars in the third panel). Second panel. Bar graph
of the differences in MI between the placenta and maternal blood cells (Y-axis) against the chromosomal locations of the CpG units (X-axis). A CpG
unit is most suitable for marker development if it further fulfills criterion #2: MI difference $0.5 (higher than the dotted line, highlighted as green
bars in the fourth panel).
doi:10.1371/journal.pone.0015069.g001
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interrogated by 6 Epityper assays (Figure 3). For each CpG unit,
a coefficient of variation (CV = standard deviation (SD)/mean) of
the MI in 10 placentas was calculated (Figure 3 and Table S8).
For each Epityper assay, a median CV of all the CpG units within
the assay was also calculated. The 4 Epityper assays with the
lowest median CV were selected for further investigation (Figure 3,
first 4 assays).
These 4 Epityper assays were performed on 6 euploid and 6
trisomy 18 placental tissue samples. No significant difference
between the two groups were found in the methylation of any
CpG unit, suggesting that placental DNA methylation was not
altered by trisomy 18 (Mann-Whitney test, P.0.05; Table S9).
Selecting for CpG sites overlapping with methylation-
sensitive restriction enzyme sites. To select specific CpG
sites that would be most promising as a noninvasive fetal DNA
marker, we performed bisulfite sequencing on the 4 selected
regions. Consistent with the MeDIP and the Epityper data, most
of the sequenced CpG sites were predominately methylated in the
placenta and almost completely unmethylated in maternal blood
cells (Figures 4A and S1). We examined these CpG sites for any
overlapping sites recognized by two commonly used methylation-
sensitive restriction enzymes, HinP1I and HpaII. There were 5, 3, 1
and 1 such sites within 100 bp from the following regions:
MAT.18.0094.1 (VAPA-APCDD1 region 1), MAT.18.0094.2
(VAPA-APCDD1 region 2), MAT.18.0071.3 (B4GALT6), and
MAT.18.0097.2 (CTDP1), respectively (Figures 4B and S1,
upward arrows). Thus, MAT.18.0094.1 was selected for deve-
loping a fetal-specific assay in maternal plasma, because the
highest number of such sites would facilitate the most complete
removal of the unmethylated maternal DNA.
This MeDIP-identified region, MAT.18.0094.1, is an intergenic
region located 73 kb downstream of the VAPA gene and 421 kb
upstream of the APCDD1 gene (Figure 4A). Hence, we refer to this
locus as VAPA-APCDD1.
Detection and characterization of digestion-resistant
VAPA-APCDD1 DNA in maternal plasma
We designed a qPCR assay to target region 1 of VAPA-APCDD1.
Since the PCR primers flanked 5 methylation-sensitive HinP1I and
HpaII sites, only VAPA-APCDD1 molecules methylated in all 5
CpG sites would result in amplifiable qPCR signal (Figure 4B).
Thus, the concentration of digestion-resistant VAPA-APCDD1
DNA detected by this qPCR assay is reflective of the level of the
methylated DNA of this potential marker.
Concentrations of digestion-resistant VAPA-APCDD1 DNA
in first-, second-, and third-trimester maternal plas-
ma. Using the above qPCR assay, we quantified the VAPA-
APCDD1 DNA in HinP1I and HpaII-digested maternal plasma
samples obtained from the three trimesters. Digestion-resistant
VAPA-APCDD1 DNA was readily detected in 26 maternal plasma
samples (5/6 (83%) first-trimester, 8/10 (80%) second-trimester
and 10/10 (100%) third-trimester samples). The concentrations of
the digestion-resistant VAPA-APCDD1 DNA in the three trimesters
were statistically significantly different (Kruskal-Wallis ANOVA
test, P,0.001) (Figure 5A).
Correlation between digestion-resistant VAPA-APCDD1
DNA and an established fetal genetic marker in maternal
plasma. To determine if there was any correlation between the
concentrations of digestion-resistant VAPA-APCDD1 DNA and
those of the ZFY DNA, an established genetic marker for detecting
male fetal DNA in maternal plasma, we analyzed the maternal
plasma samples from 13 pregnant women bearing male fetuses in
the previous experiment. Digestion-resistant VAPA-APCDD1 and
ZFY concentrations were positively correlated (r=0.91;
P,0.00001; Spearman correlation) (Figure 5B). Both assays were
optimized to run under identical PCR thermal profiles (Table S3)
and showed similar efficiencies as reflected by the slopes (23.77
and 23.53 for the VAPA-APCDD1 and the ZFY assays,
respectively) and y-intercepts (39.7 Cq and 38.9 Cq for the
VAPA-APCDD1 and the ZFY assays, respectively) of the two
calibration curves.
Postpartum clearance of digestion-resistant VAPA-
APCDD1 DNA in maternal plasma. To further investigate if
digestion-resistant VAPA-APCDD1 DNA in maternal plasma would
be cleared upon delivery of the fetus, we collected pre-delivery and
24-hour post-delivery maternal plasma samples from 10 other
pregnant women. In all 10 cases, the digestion-resistant VAPA-
APCDD1 DNA was rapidly cleared from maternal plasma to
almost undetectable levels (Figure 5C), demonstrating that its
existence in maternal plasma was fetal-specific. The plasma
concentrations of digestion-resistant VAPA-APCDD1 DNA before
and after delivery of the fetuses were statistically significantly
Table 1. MeDIP-identified loci with CpG sites useful for developing fetal epigenetic markers in maternal plasma.
Locus ID
Number of CpG
fulfilling criteria
#1 and #2
Chromosomal
location on
chr 18
Associated
gene symbol Associated gene
RefSeq accession
number, region
MAT.18.0094 19 10022563-10023955 VAPA-APCDD1 VAMP (vesicle-associated membrane protein)-
associated protein A, 33kDa,a n dAdenomatosis
polyposis coli down-regulated 1
NM_003574 and
NM_153000, inter-
genic region
MAT.18.0071 5 27485628-27487511 B4GALT6 Beta-1,4-galactosyltransferase 6 NM_004775, intron
MAT.18.0097 4 75542484-75543900 CTDP1 Carboxy-terminal domain, RNA polymerase II,
polypeptide A phosphatase, subunit 1
NM_004715, intron
MAT.18.0096 4 72292238-72293387 ZNF516 Zinc finger protein 516 NM_014643, intron
TAS.18.1887 3 72227405-72228513 ZNF516 Zinc finger protein 516 NM_014643, intron
TAS.18.0841 2 27486040-27487378 B4GALT6 Beta-1,4-galactosyltransferase 6 NM_004775, intron
MAT.18.0098 2 54075774-54077141 NEDD4L Neural precursor cell expressed, developmen
tally down-regulated 4-like
NC000018.9, intron
TAS.18.0675 1 19035725-19036654 CABLES1 Cdk5 and Abl enzyme substrate 1 NM_138375, intron
Genomic locations are defined according to the human genome database in the UCSC Genome Browser (March 2006 assembly, hg18). chr, chromosome.
doi:10.1371/journal.pone.0015069.t001
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PLoS ONE | www.plosone.org 5 November 2010 | Volume 5 | Issue 11 | e15069Figure 2. DNA methylation levels by MeDIP and the Epityper on 5 promising loci for marker development. Left panels. The positions of
these 5 loci (dotted-line boxes) in relation to the associated genes, and their exons (blocks) and introns (lines) are shown. The genes are shown in the
direction of mRNA transcription from left to right. The bar graph below each gene shows the difference in the MeDIP-chip probe signals between the
placenta and maternal blood cells plotted against chromosomal location. Each vertical bar represents the signal from one probe. The average inter-
probe distance is 35 bp. A positive value implies a higher DNA methylation level in the placenta, compared with maternal blood cells. Horizontal lines
with arrows at both ends indicate the regions spanned by the Epityper assays (a–f). Right panels. The median DNA methylation indices (MI) of CpG
units within the Epityper assays are shown in a grey intensity scale. Asterisks indicate the CpG units with higher DNA methylation in five placentas
than five maternal blood cell samples (Mann-Whitney test, P,0.05). The chromosomal locations and MI of each CpG unit are listed in Table S7.
doi:10.1371/journal.pone.0015069.g002
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successful DNA extraction, we quantified the total DNA amount
by the VAPA-APCDD1 DNA qPCR assay, and detected DNA in all
pre-delivery and post-delivery maternal plasma samples before
enzyme digestion. As a control for complete enzyme digestion, a
qPCR assay was designed to target a region on the b-actin gene,
which was known to be completely unmethylated (MI=0.00) in
both the placenta and maternal blood cells (Figures 4B and S2),
and no signals were detected in any of the HinP1I- and HpaII-
digested maternal plasma samples. The lower limits of detection of
the b-actin and VAPA-APCDD1 qPCR assays were both 3 copies
per reaction, as determined by the methods in File S1.
Epigenetic-genetic (EGG) dosage analysis of fetal
chromosome 18 in maternal plasma by digestion-
resistant VAPA-APCDD1 DNA
Digital PCR assays for the VAPA-APCDD1, ZFY and b-
actin DNA. To detect the relatively small (,1.5-fold) increase in
the dosage of chromosome 18 in trisomy 18, the digital PCR
platform, which featured a higher precision than conventional
qPCR, was used. These digital PCR assays were first validated in
HinP1I and HpaII-digested plasma samples collected from 5
pregnant women before and after delivery, and 4 non-pregnant
females. By these digital PCR assays, digestion-resistant VAPA-
APCDD1 DNA and ZFY DNA were detected in pre-delivery
maternal plasma samples, but were almost undetectable in post-
delivery maternal plasma and non-pregnant female plasma
samples (Table S10). b-actin DNA was not detected in all 3
groups of digested samples (Table S11).
EGG dosage analysis of chromosome 18 in the
placenta. Since the placenta is the main source of fetal DNA
in maternal plasma, we tested EGG analysis in the placenta before
attempting it in maternal plasma. Digital PCR assays for VAPA-
APCDD1 and ZFY DNA were performed on HinP1I- and HpaII-
digested DNA samples extracted from placental tissues of five
trisomy 18 and five euploid male fetuses. The ratio of digestion-
resistant VAPA-APCDD1 to ZFY was calculated for each sample.
These ratios were significantly higher in the trisomy 18 placentas
than the euploid placentas (Mann-Whitney test, P=0.029; Figure
S3). A reference interval, defined as the mean ratio digestion-
resistant VAPA-APCDD1 to ZFY 61.96 SD, was calculated from
the euploid placentas as 1.20–1.66. The ratios in all of the trisomy
18 placenta were above the upper reference limit (Figure S3).
EGG dosage analysis of fetal chromosome 18 in maternal
plasma. Since the digestion-resistant VAPA-APCDD1 DNA and
ZFY DNA are fetal-specific in maternal plasma, we reasoned that
EGG dosage analysis of the fetus or the placenta could also be
performed in maternal plasma. Maternal plasma samples were
collected from 27 women with euploid male fetuses, and 9 women
with trisomy 18 male fetuses. The median gestational ages at
sample collection were 14.1 weeks (IQR, 12.9–16.6) and 13.3
weeks (IQR 12.9–14.5) among the euploid and trisomy 18 fetuses,
respectively. The HinP1I- and HpaII-digested plasma samples were
subjected to digital PCR assays for VAPA-APCDD1 and ZFY DNA
(Figure S4). To facilitate a fair comparison, we diluted each plasma
sample to a comparable average template concentration (m)o fZFY
(reference) molecules per reaction well. The median m values were
0.08 and 0.05 per reaction well for the euploid and trisomy
samples, respectively. The ratio of digestion-resistant VAPA-
APCDD1 to ZFY was calculated for each sample. The ratios of
digestion-resistant VAPA-APCDD1 to ZFY were significantly higher
in maternal plasma samples of trisomy 18 fetuses than those of
euploid fetuses (Mann-Whitney test, P,0.001) (Figure 6). A
reference interval of 0.34–3.04 was calculated for the 27 maternal
plasma samples from euploid pregnancies. The ratio of one
euploid sample fell outside the reference interval. The ratios of 8
out of 9 trisomy 18 samples were above the upper reference limit.
b-actin DNA was essentially undetectable by the digital PCR
assay in all of the 36 digested maternal plasma DNA samples,
implying that complete digestion had occurred. Ten cases were
selected for comparing the detectable concentrations of b-actin
DNA before and after digestion. b-actin DNA was detectable in all
the maternal plasma samples before, but not after, digestion
(Figure S5).
Discussion
Using MeDIP-chip analysis, the Epityper and bisulfite sequenc-
ing, we have systematically identified methylated fetal epigenetic
markers on chromosome 18. We have also demonstrated that one
such marker, namely the digestion-resistant VAPA-APCDD1 DNA,
was readily detectable in maternal plasma during pregnancy, but
rapidly cleared to almost undetectable levels upon delivery of the
fetus. Further characterization has shown that the concentrations
of this novel marker in maternal plasma were positively correlated
with those of an established fetal genetic marker.
Since these data have suggested that this digestion-resistant
VAPA-APCDD1 DNA was predominantly derived from the fetus in
maternal plasma, we further applied it for the EGG dosage analysis
of fetal chromosome 18 in maternal plasma. We have determined
the ratio of digestion-resistant VAPA-APCDD1 to ZFY in maternal
plasma samples involving 9 trisomy 18 male fetuses, and 27 euploid
male fetuses. A reference interval of this ratio calculated from the
euploid samples was calculated. We then observed the ratios of 8
trisomy 18 fetuses, and only 1 euploid fetus was higher than the
Figure 3. Inter-individual variation of placental methylation levels in promising regions for marker development. For each CpG unit,
the coefficients of variation (CV) of the MI in 10 euploid first-trimester placentas are plotted. For each region, the median CV of all CpG units is shown.
doi:10.1371/journal.pone.0015069.g003
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threshold, all except one trisomy 18 fetuses was detected (i.e. 1 false
negative), and only one euploid was also detected (i.e. 1 false
positive). The sensitivity and specificity were 88.9% and 96.3%,
respectively, for this EGG analysis in maternal plasma.
Of note, in this EGG analysis, we have quantified the reference
chromosome by a fetal genetic marker, i.e. the ZFY DNA, instead
of a fetal epigenetic marker, e.g. the hypermethylated RASSF1A
[17]. This is because we have previously shown that the dosage
analysis had greater power in distinguishing the trisomic from the
Figure 4. DNA methylation levels by bisulfite sequencing in the most promising locus for marker development. (A) Top panel. The
genomic location of one promising locus in relation to two associated genes. The locations of two other promising loci are shown in Figure S1. Middle
panel. Two regions, which were identified by MeDIP as possessing higher methylation in the placenta relative to maternal blood cells, was analyzed
by bisulfite sequencing. See Figure 2 for the legend on the bar graph for MeDIP. Bottom panel. Single-base DNA methylation levels determined by
bisulfite sequencing. For each sample, 8 randomly-picked clones (rows) were scored for each CpG site (column). Filled circles, methylated CpG sites.
Empty circles, unmethylated CpG sites. Upward arrows, cutting sites of the methylation-sensitive restriction enzymes HpaII and HinP1I. (B) Design of
qPCR and digital PCR assays for region 1 of VAPA-APCDD1 (5 cutting sites), ZFY (0 cutting sites), and b-actin DNA (4 cutting sites). Block arrows, PCR
primers. Rectangle, hydrolysis probe.
doi:10.1371/journal.pone.0015069.g004
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PLoS ONE | www.plosone.org 8 November 2010 | Volume 5 | Issue 11 | e15069Figure 5. Characteristics of digestion-resistant VAPA-APCDD1 DNA in maternal plasma. (A) Box plot of the concentrations of this fetal
epigenetic marker in the first-, second- and third-trimester pre-delivery maternal plasma. The line inside each box denotes the median. Limits of the
box denote the 25
th and 75
th percentiles. Whiskers denote the 10
th and 90
th percentiles. Filled circles denote the outliers. The results of the Kruskal-
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fetal genetic marker instead of a fetal epigenetic marker [11]. For
fetal epigenetic markers, there are small degrees of heterogeneity
in the DNA methylation levels between samples. If we determined
the relative ratio between an epigenetic marker on the aneuploid
chromosome and another epigenetic marker on a reference
chromosome, the combined variance caused by the heterogeneous
DNA methylation levels in both epigenetic markers would be
large. The resultant inter-individual variation in the chromosome
dosage ratio would be too large to discriminate trisomy from
euploid cases. Thus, it is preferable to quantify the reference
chromosome by a fetal genetic marker.
Of a similar concern, to minimize the inter-individual variability
in the DNA methylation level of the fetal epigenetic marker used
for quantifying the potentially aneuploid fetal chromosome 18, we
have studied how the DNA methylation levels of each CpG unit
varied across different individuals by the Epityper. Among the six
potential markers, the median of the inter-individual CVs was
observed to vary from 8% to 38% (Fig. 3). The data suggested that
the development of fetal epigenetic markers by MeDIP-based
study should be followed up by quantitative DNA methylation
studies at single CpG resolution. Otherwise, a low degree of inter-
individual variation, which is important for developing quantita-
tive applications such as the assays for the EGG analysis, could not
be guaranteed by the MeDIP-based study alone.
Additionally, our data have suggested that not every CpG site in
the MeDIP-identified regions could fulfill the stringent criteria for
developing fetal epigenetic marker in maternal plasma. Some CpG
sites might possess undesirably high levels of DNA methylation in
the maternal blood cells (Figure 1B, not fulfilling criterion #1),
thus preventing the removal of the maternal DNA sequence in
maternal plasma. On the other hand, some CpG sites might not
have high enough DNA methylation levels in the placenta relative
to maternal blood cells, thus preventing the specific detection of
the fetal DNA sequence in maternal plasma (Figure 1B, not
fulfilling criterion #2). Thus, the quantitative DNA methylation
data provided by the Epityper for each CpG unit within the
MeDIP-identified regions were indispensable for developing fetal
epigenetic markers (Figure 3). The Epityper data have facilitated
us to select for a suitable epigenetic signature, with marked
difference between the placenta and maternal blood cells and with
the least inter-individual variation, to target the fetal chromosome
18 in maternal plasma for the EGG analysis.
In this study, we performed the EGG analysis only in
pregnancies involving male fetuses because a precise digital PCR
assay targeting the Y-chromosome, namely the ZFY DNA assay, is
well established in our laboratory [5]. However, we envision that
this type of EGG analysis can be adopted for pregnancies
involving female fetuses, because any fetal DNA sequence,
including an autosomal sequence, that is inherited only from the
father, and is located on a chromosome unaffected by the
concerned trisomy, can serve as a fetal genetic marker for
quantifying the reference chromosome. Through the latter
approach, EGG analysis can be performed for both female and
male fetuses.
In this study, we demonstrated the feasibility of applying the
EGG approach for the noninvasive prenatal detection of fetal
trisomy 18. The diagnostic accuracy of the test requires further
evaluation in a larger cohort. Nevertheless, we are the first to use a
bisulfite-independent approach to detect a methylated epigenetic
marker for fetal chromosome 18 in first-trimester maternal plasma,
and to use this approach to achieve the noninvasive detection of
Figure 6. Comparison of chromosome dosage in DNA samples from euploid and trisomy 18 maternal plasma. For each sample, the
ratio of digestion resistant VAPA-APCDD1 DNA (chr18) and ZFY DNA (chrY) is plotted. The reference interval of the euploid ratios was calculated as
0.34–3.04 (bound by the dotted lines).
doi:10.1371/journal.pone.0015069.g006
Wallis ANOVA test showed that there are significant differences among the three trimesters (P,0.001). The P-values of the pairwise comparisons with
significant differences are shown (Dunn’s test). (B) Concentrations of the epigenetic (Y-axis) and genetic (X-axis) markers in 13 maternal plasma
samples (Spearman rank order correlation test, P,0.00001, R=0.91). (C) The concentrations of this marker in 10 pairs of pre-delivery and post-delivery
maternal plasma (Wilcoxon Signed-rank test, P=0.002). Corresponding plasma samples from the same pregnant women are connected by a line.
doi:10.1371/journal.pone.0015069.g005
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PLoS ONE | www.plosone.org 10 November 2010 | Volume 5 | Issue 11 | e15069fetal trisomy 18 in early gestation. Compared with tests based on
massivelyparallel genomicsequencing,the approachdescribedhere
might represent a lower ‘barrier for entry’ by many laboratories
interested in noninvasive prenatal diagnosis, as the equipment and
bioinformatics support requirements are much lower [38].
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Figure S1 DNA methylation levels by bisulfite sequenc-
ing in two promising loci for developing fetal epigenetic
markers. Data on each locus are shown in two panels, each of
which contains 3 sub-panels. Top sub-panel. The genomic location
of the promising locus in relation to the associated gene. Middle
sub-panel. The locus, which was identified by MeDIP as possessing
higher methylation in the placenta relative to maternal blood cells,
was analyzed by bisulfite sequencing. See Figure 2 for the legend
on the bar graph for MeDIP. Bottom sub-panel. Single-base DNA
methylation levels by bisulfite sequencing. For each sample, 8
randomly-picked clones (rows) were scored for each CpG site
(column). Filled circles, methylated CpG sites. Empty circles,
unmethylated CpG sites. Upward arrows, cutting sites of the
methylation-sensitive restriction enzymes HpaII and HinP1I.
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Figure S2 DNA methylation levels by bisulfite sequenc-
ing in the b-actin gene. For each sample, 8 randomly-picked
clones (rows) were scored for each CpG site (column). Filled
circles, methylated CpG sites. Empty circles, unmethylated CpG
sites. Upward arrows, cutting sites of the methylation-sensitive
restriction enzymes HpaII and HinP1I.
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Figure S3 Comparison of chromosome dosage in DNA
samples from euploid and trisomy 18 placental tissues.
For each sample, the ratio of digestion-resistant VAPA-APCDD1
DNA (chr18) and ZFY DNA (chrY) is plotted. The reference
interval of the euploid ratios was calculated as 1.20–1.66 (bound
by the dotted lines).
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Figure S4 Workflow of the EGG chromosome dosage
analysis of maternal plasma samples. Methylation-sensitive
restriction enzymes, HinP1I and HpaII. VAPA-APCDD1/ZFY
assay, a duplex digital PCR assay.
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Figure S5 Concentrations of b-actin DNA in EGG-
analyzed plasma samples before and after enzyme
digestion. b-actin DNA was essentially undetectable by the
digital PCR assay in any of the 36 EGG-analyzed plasma samples
after digestion. Further analysis of ten maternal plasma samples (8
euploid and 2 trisomy 18 cases) before digestion was also
performed by this digital PCR assay. Data of these 10 paired
samples are shown.
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